Title of the article: Current Review of the SARS-CoV-2 Omicron
Subvariant BF.7 (BA.184.108.40.206) Virology and Preventing Strategies.
Since its identification in late 2019 the novel coronavirus, severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) In Wuhan, China,
by the World Health Organization (WHO), which cause the coronavirus
disease 2019, it is rapidly spreading, resulting in the global pandemic.
As of 19 December 2022, a total of 64 million (649,038,437) confirmed
cases including 6,645,812 deaths have been reported across the world.
Over time, the SARS-CoV-2 acquired genetic mutations resulting in
multiple types of SARS-CoV-2 variants and subvariants that have been
confirmed. The Omicron (B.1.1.529) variant was identified later in
November 2021, with enhanced immune escape and was followed with various
sublineages BA.1, BA.2, BA.3, BA.4 and BA.5 and Other sublineages BQ.1,
BQ.11, BF.7, BA.2.75, and XBB due to mutations in the spike protein of
the SARS-CoV-2. In response to the current surge in the COVID-19 reports
by Omicron subvariant BF.7 also known as BA.2.75.2, in China and other
countries, triggering global alarm. The present review was conducted to
understand the virology, factors associated with increased
transmissibility with BF.7 and possible urgent preventing strategies to
be taken to curtail the novel omicron variants outbreak across the